ESMO 2012 Congress: A path for medical oncology innovations

"The oncology field is going to explode within the next five years and in ten years from now oncology will be drastically different from what it is today: what we are going to see at ESMO 2012 in Vienna will give a broad overview of how new technologies can improve the tailoring of cancer therapies for the benefit of our patients." --Martine Piccart, ESMO and ESMO 2012 Congress President

More than 17,000 participants from over 120 different countries are coming to Vienna for the 37th congress of the European Society for Medical Oncology, including oncology professionals, healthcare policy makers, patient groups, pharmaceutical industry (85 exhibitors), cancer foundations and representatives of international media.

Over 200 program hours with 140 sessions, of which 110 presenting scientific results on cancer research progress in 2012, including late-breaking abstracts on gastrointestinal tumors, lung cancer, genitourinary tumors, breast cancer, gynecological cancers. Over 300 international experts will share best knowledge in cancer research, treatment and patient care.

Congress Program Highlights

More than 2,200 abstracts submitted, including 44 late-breaking abstracts, possibly foreshadowing important changes in clinical practice – More details will be available at the end of July
Genomics opening new doors in the development of cancer treatments… – Read the interview with Dr Martine Piccart, ESMO President http://www.esmo.org/events/vienna-2012-congress/program/committe-member-erika-martinelli.html
Personalized medicine: the importance of patient selection in treatment efficacy from the early phases of drug development
Issues in the management of cancer in young women
Cancer prevention and screening: evidence-based answers to critical questions, including inherited cancers, and European screening guidelines
Public policy:
- The need for harmonization of the approval process and reimbursement systems of new oncology drugs in Europe
- Cost effectiveness and clinical trials: a new paradigm?
- The role of cancer registries in support of planning and assessing population based oncology outcomes
First presentation of the findings of the International Collaborative Project on the availability and accessibility of opioids for the management of cancer pain
Four keynote lectures: for the first time oriented towards transversal topics, reaching beyond individual disease types, providing a topline picture of the evolution of cancer knowledge and cancer care
Controversy sessions: six lively and thought-provoking discussions on particularly hot topics based on latest research results
ESMO Clinical Practice Guidelines sessions: open discussions on individual cases to share the best of cancer care based on newly released and updated standards
ESMO Designated Centers of Integrated Oncology and Palliative Care announced as centers of excellence for patient care in Europe
ESMO Award, Hamilton Fairley Award, ESMO Lifetime Achievement Award and Georges Mathé Award recipients announced, to recognize prominent oncologists who have made outstanding contributions to the development of oncology and are internationally renowned for their achievements in cancer science and clinical / laboratory research
"2084": An inspirational and provocative play in three acts addressing the obstacles to conducting clinical research in the ever-evolving field of oncology…
"I think you're forgetting something, the authors of that trial never got prospective consent for this test to be used on archival patient's material."
"How could they? The assay was only described two years ago!"
"But that's not the point, you should know by now that all biological studies on any materials taken from patients in clinical trials for one purpose cannot be used for another purpose without the patient's fully informed consent."
"But that's absurd, all those patients will have died decades ago. Am I to get consent posthumously?"

The ESMO 2012 Congress full program is available at http://www.esmo.org/events/vienna-2012-congress/program.html

Meeting venue and accommodation

The ESMO 2012 Congress will take place at the Austria Center Vienna, which is located 15 minutes from the city center, within walking distance from the underground station (U1 line) and just a 25 minutes' drive from the airport.

ACV - AUSTRIA CENTER VIENNA http://www.acv.at/
Bruno-Kreisky-Platz 1
1220 Vienna

As Vienna is a highly popular tourist destination, we advise you to book your hotel accommodation as soon as possible: http://www.esmo.org/events/vienna-2012-congress/accommodation.html

Media registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO 2012 Media Policy http://www.esmo.org/fileadmin/media/pdf/2012/events/vienna/ESMO-media-policy-update-2012-06.pdf .

To register for the event, please fill out the Complimentary Media Registration Form

Media registration in advance is strongly recommended (deadline: Monday, 24 September 2012).

A fully equipped ESMO Press Center will be available to registered journalists, including a press room with technical facilities (computers, wi-fi internet, telephones, photocopier, etc.), private interview rooms, storage cabinets for your technical equipment. On-site staff will be permanently at your disposal for any question and to facilitate one-on-one interviews with researchers and key opinion leaders, both in presence and remotely.

ESMO Press Program

The official ESMO 2012 Press Program will be developed in the following months, after review and acceptance of submitted abstracts. Details will be progressively uploaded on http://www.esmo.org/events/vienna-2012-congress/press.html.

In the meantime you can mark your diaries with important appointments for the press: ESMO 2012 Congress Preliminary Press Program Overview.

###

[ | E-mail |

Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.